In short
This article explores the use of Regtivex, an innovative drug being studied in clinical trials for kidney transplant recipients. Regtivex is part of a new approach that combines regulatory T cell therapy with other treatments to potentially improve transplant outcomes and reduce the need for long-term immunosuppression.
At a glance
- Drug Name
- Regtivex (Expanded Tregs_04)
- Trial Phase
- Phase I and II integrated trial
- Target Condition
- Kidney transplantation
- Main Objectives
- 1. Examine safety of Regtivex with tocilizumab and donor bone marrow; 2. Assess chimerism levels within first month post-transplant
- Key Secondary Objectives
- 1. Evaluate potential for immunosuppression reduction; 2. Assess changes in immune system indicating tolerance; 3. Monitor frequency of rejection episodes; 4. Assess kidney graft function
- Administration Method
- Intravenous infusion
- Key Eligibility Criteria
- 1. Adults (18+ years); 2. Planned living donor kidney transplant recipients; 3. ABO-compatible, non-HLA-identical donors; 4. Negative for donor-specific antibodies
- Primary Endpoints
- 1. Safety: Incidence of GVHD, impaired graft function, or patient death; 2. Efficacy: Peak chimerism levels within first month
What is REGTIVEX?
REGTIVEX, also known as "Expanded Tregs_04" or "Expanded regulatory T cells_04", is an innovative medical treatment being studied for patients undergoing kidney transplantation. It is classified as a cell therapy, which means it uses living cells as a therapeutic agent. Specifically, REGTIVEX is made up of regulatory T cells, a type of immune cell that helps control the body's immune responses.
How REGTIVEX Works
REGTIVEX is designed to help kidney transplant recipients by modulating their immune system. The therapy involves:
- Expanding the patient's own regulatory T cells in a laboratory
- Infusing these expanded cells back into the patient
- Combining this treatment with other medications to create a more tolerant environment for the transplanted kidney
The goal is to reduce the risk of the body rejecting the new kidney while potentially allowing for a reduction in other immunosuppressive medications.
Clinical Trial Overview
REGTIVEX is currently being studied in a clinical trial called "Trex". This trial is designed to evaluate the safety and effectiveness of REGTIVEX when used alongside other treatments in patients receiving kidney transplants from living donors who are not perfectly matched in terms of their HLA (Human Leukocyte Antigen) type.
The main objectives of the trial are:
- To examine the safety of REGTIVEX therapy when used with tocilizumab (another medication) and donor bone marrow in kidney transplant recipients
- To assess chimerism levels (the presence of donor cells in the recipient's body) within the first month after transplant
Potential Benefits
The researchers hope that REGTIVEX therapy may offer several benefits to kidney transplant recipients:
- Potentially reducing the need for long-term immunosuppressive medications
- Promoting a more tolerant immune environment for the transplanted kidney
- Possibly decreasing the frequency of rejection episodes
- Potentially improving long-term kidney graft function
These potential benefits are being carefully studied in the clinical trial to determine if REGTIVEX can indeed provide these advantages.
Eligibility Criteria
The clinical trial has specific criteria for who can participate. Some key eligibility factors include:
- Being 18 years or older
- Planning to receive a kidney transplant from a living donor
- The donor and recipient not being perfectly HLA-matched
- Not having certain viral infections (like HIV or chronic hepatitis)
- Not having had a previous organ transplant
It's important to note that there are additional criteria, and a healthcare provider would need to assess each individual case.
Safety Considerations
As with any new medical treatment, safety is a top priority in the REGTIVEX clinical trial. The researchers are closely monitoring for any potential side effects or complications, including:
- Graft-versus-host disease (GVHD): A condition where donor cells attack the recipient's body
- Impaired graft function: Monitoring if the transplanted kidney is working properly
- Overall patient health and survival
These safety aspects are being carefully evaluated throughout the 12-month period following the transplant.